Related Experiment Videos
Are all 5-HT3 receptor antagonists the same?
P L Andrews1, P Bhandari, P T Davey
1St. George's Hospital Medical School, Tooting, London, U.K.
Abstract:
A number of 5-HT3 receptor antagonists are currently in clinical development as antiemetics. In this paper we focus on two of these antagonists, granisetron and ondansetron, and compare their antimetic activity against cisplatin (10 mg/kg i.v.)- or whole body X-irradiation (200 rads)-induced emesis in the conscious ferret. The results presented here have been discussed in the light of the recently published literature. Our data suggest that in comparison to ondansetron, granisetron is a more potent, longer acting and pharmacologically "cleaner" compound with a more conventional dose-response profile. The possible impact of these features upon the performance of these compounds in the clinic is discussed particularly with respect to dosing regimens and clinical efficacy. Differences appear to be emerging between granisetron and ondansetron in both these respects, although a direct head-to-head clinical comparison has yet to be carried out. This would involve studies monitoring a sufficiently high number of patients receiving severely emetogenic regimes to allow real clinical differences to be detected with the appropriate statistical power.
Insights
Granisetron demonstrates superior antiemetic effects compared to ondansetron in ferret models. This 5-HT3 receptor antagonist shows greater potency and duration, suggesting potential clinical advantages.
Area of Science:
- Pharmacology
- Neuroscience
- Oncology
Background:
- 5-HT3 receptor antagonists are crucial antiemetics.
- Granisetron and ondansetron are key compounds in this class.
- Understanding their comparative efficacy is vital for clinical application.
Purpose of the Study:
- To compare the antiemetic activity of granisetron and ondansetron.
- To evaluate their efficacy against cisplatin-induced and radiation-induced emesis.
- To analyze pharmacological profiles and potential clinical implications.
Main Methods:
- Utilized conscious ferret models to assess emesis.
- Administered cisplatin (10 mg/kg i.v.) and whole-body X-irradiation (200 rads) to induce emesis.
- Compared the antiemetic responses to granisetron and ondansetron.
Main Results:
- Granisetron exhibited greater potency and longer duration of action than ondansetron.
- Granisetron displayed a more conventional dose-response profile.
- Pharmacological differences suggest distinct clinical performance.
Conclusions:
- Granisetron appears to be a more effective antiemetic than ondansetron in preclinical models.
- Emerging differences in potency, duration, and profile may impact clinical dosing and efficacy.
- Further head-to-head clinical trials are needed to confirm these findings in patients.